Celldex Therapeutics
CLDX
$42.56
Share price
4.16%
Change (1 day)
35.15%
Change (1 year)
Categories
Celldex Therapeutics (CLDX) - P/B ratio
P/B ratio as of May 2024 : 6.28
According to Celldex Therapeutics's latest financial reports the company has a price-to-book ratio of 6.28.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Celldex Therapeutics - P/B ratio (from 2001 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 5.05 | -21.47% |
| 2022-12-31 | 6.44 | 49.5% |
| 2021-12-31 | 4.30 | 29.88% |
| 2020-12-31 | 3.31 | 723.36% |
| 2019-12-31 | 0.4025 | 40.68% |
| 2018-12-31 | 0.2861 | -82.49% |
| 2017-12-31 | 1.63 | 21% |
| 2016-12-31 | 1.35 | -74.68% |
| 2015-12-31 | 5.33 | -30.95% |
| 2014-12-31 | 7.72 | 14.34% |
| 2013-12-31 | 6.76 | 49.84% |
| 2012-12-31 | 4.51 | 169.96% |
| 2011-12-31 | 1.67 | -4.83% |
| 2010-12-31 | 1.75 | -12.51% |
| 2009-12-31 | 2.01 | -70.91% |
| 2008-12-31 | 6.90 | -121.04% |
| 2007-12-31 | -32.8 | -170.71% |
| 2006-12-31 | 46.3 | 594.29% |
| 2005-12-31 | 6.67 | 72.05% |
| 2004-12-31 | 3.88 | -38.91% |
| 2003-12-31 | 6.35 | 190.68% |
| 2002-12-31 | 2.18 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 1.76 | -72.01% | 🇺🇸 USA |
 Amgen AMGN | 24.0 | 281.83% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 5.43 | -13.52% | 🇬🇧 UK |
 Titan Pharmaceuticals
TTNP | 0.9222 | -85.30% | 🇺🇸 USA |
 Seagen
SGEN | 16.9 | 169.65% | 🇺🇸 USA |
 Agenus
AGEN | -1.77 | -128.23% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | 0.2663 | -95.76% | 🇺🇸 USA |